Clinical Trial Update: Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating amantadine hydrogen chloride ER tablets in Parkinson's disease patients with Levodopa-induced dyskinesia was terminated with posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Levodopa-induced Dyskinesia
• Parkinson Disease

Drugs mentioned

• amantadine hydrochloride extended-release (amantadine HCl ER)

Snippet

Sponsor: Adamas Pharmaceuticals, Inc. | Conditions: Parkinson's Disease, Levodopa Induced Dyskinesia (LID) | Phase 3 | Status: TERMINATED | Results posted: 2019-04-02